Developing Differentiated Medicines 

PureTech is developing medicines for devastating diseases including intractable cancers, lymphatic, GI diseases, CNS disorders, inflammatory and immunological diseases.

Explore our Pipeline

Exploring the Brain Immune Gut (BIG) axis

See Our Science

24 product candidates

14 are clinical stage

1 FDA cleared product

Explore our pipeline

Relationships with major pharma companies

Amgen Novartis Lilly Merck Boehringer Ingelheim Bristol-Myers Squibb Janssen Roche
Meet Our Global Collaborators

Team of industry leaders and experts

Meet Our Team
Publications
ALL >
Publications
Nature Neuroscience: CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature

Full Article

Publications
Internal Pipeline
PureTech's Lymphatic Leap

FULL ARTICLE

Publications
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation
Press releases
2019-11-21
PureTech Affiliate Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock

Continue

Press releases
2019-11-18
PureTech Affiliate Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

Continue

Press releases
2019-11-15
PureTech’s Independent Affiliate resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint

Continue